Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Shares of Biogen Inc. tumbled more than 5% on Wednesday morning, hitting their lowest levels since January 2013, as the ...